Spectrum Pharmaceuticals has withdrawn its Biologics License Application (BLA) for eflapegrastim, a granulocyte colony-stimulating factor (G-CSF) therapy that the company had hoped to sell under the brand name Rolontis.
Spectrum Pharmaceuticals has withdrawn its Biologics License Application (BLA) for eflapegrastim, a granulocyte colony-stimulating factor (G-CSF) therapy that the company had hoped to sell under the brand name Rolontis.
According to the drug maker, the FDA requested additional manufacturing information, though the agency did not ask for further clinical studies. The company said that it needs more time to provide some of the requested information to the agency, and that it would be unlikely to be able to meet the FDA’s request prior to the end of the initial review period.
Spectrum says that it plans to resubmit a revised BLA for eflapegrastim in the future. “We are continuing to have productive discussions with the FDA and will deliver the additional information needed to support the application,” Joe Turgeon, president and chief executive officer of Spectrum, said in a statement. “We remain confident in the Rolontis program and look forward to a successful resubmission and its ultimate approval.”
The drug had been expected to compete with pegfilgrastim (Neulasta) and its biosimilars (the recently FDA-approved and US-launched Fulphila and Udenyca) for market share; the long-acting G-CSF agent has demonstrated a 2- to 3-fold increase in area under the time‐concentration curve for absolute neutrophil count versus pegfilgrastim when administered at similar doses, and the proposed drug also demonstrated comparable efficacy compared with pegfilgrastim in an open-label study in patients with breast cancer who were receiving docetaxel and cyclophosphamide. Finally, no new safety concerns were noted during the clinical program.
However, now that biosimilars of pegfilgrastim are entering the marketplace and are competing with Neulasta, it remains to be seen whether there will be an appetite for a costly brand-name G-CSF agent among a field of less expensive biosimilar options.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.